Valuation : Lexington Biosciences, Inc.

Market Cap 3.94K 2.86K 2.46K 2.31K 2.11K 271K 3.96K 27.41K 10.61K 139K 10.74K 10.51K 441K P/E 2022
-
P/E 2023 -
Enterprise Value 3.94K 2.86K 2.46K 2.31K 2.11K 271K 3.96K 27.41K 10.61K 139K 10.74K 10.51K 441K EV / Sales 2022
-
EV / Sales 2023 -
Free-Float
13.79%
Yield 2022 *
-
Yield 2023 -
28/11/24 Registered Plan Private Investments Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
23/08/24 Registered Plan Private Investments Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
25/05/24 Registered Plan Private Investments Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
01/05/24 Registered Plan Private Investments Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
30/04/24 Registered Plan Private Investments Inc. Auditor Raises 'Going Concern' Doubt CI
29/11/23 Registered Plan Private Investments Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
05/09/23 Registered Plan Private Investments Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
30/05/23 Registered Plan Private Investments Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
03/05/23 Registered Plan Private Investments Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
02/05/23 Registered Plan Private Investments Inc. Auditor Raises 'Going Concern' Doubt CI
29/11/22 Registered Plan Private Investments Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
30/08/22 Registered Plan Private Investments Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
30/05/22 Registered Plan Private Investments Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Manager TitleAgeSince
Chief Executive Officer 62 16/04/2020
Director of Finance/CFO 68 -
Director TitleAgeSince
Director/Board Member 68 21/12/2016
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+6.67% - - 2.74K
-2.10%-2.60%-19.75%+5.33% 187B
-1.55%+0.70%-0.33%+15.91% 120B
-1.16%-1.16%+9.83%+84.10% 63.15B
-3.40%-5.18%+13.70%+44.83% 52.36B
-2.76%-3.99%-6.22%-32.65% 50.32B
-3.30%-5.87%+8.78%-18.69% 33.17B
-3.28%+0.74% - - 32.1B
-1.02%-0.50%+33.10%-14.30% 23.93B
-1.98%-7.53%-12.06%+6.09% 22.7B
Average -2.05%-0.72%+3.38%+11.33% 65.07B
Weighted average by Cap. -2.14%-0.77%-3.45%+14.64%

Financials

2022 2023
Net sales - -
Net income -176K -128K -110K -103K -94.29K -12.11M -177K -1.22M -474K -6.19M -480K -469K -19.7M -177K -129K -111K -104K -95.05K -12.21M -178K -1.23M -477K -6.24M -484K -473K -19.86M
Net Debt - -
Logo Lexington Biosciences, Inc.
Lexington Biosciences Holdings Corp., formerly Lexington Biosciences Inc., is a Canada-based medical device company, which core business is to develop and commercialize non-invasive diagnostic product HeartSentry to monitor cardiovascular health by assessing the function of a person’s vascular endothelium - the vital innermost lining of a person’s cardiovascular system. The device measures the function of the endothelium, the cells that line all arteries and are critical to the prevention of atherosclerosis, heart attacks and stroke. The company is in the final stages of releasing the developed product for clinical studies. The Company's goal is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person’s cardiovascular health.
Employees
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!